RxDoctor Payments Data

Eric Marks, MD

Medical Oncology · Boston, MANPI 1952729717

Payments from drug & device makers

What this record shows

That places this record below the midpoint for medical oncology clinicians in MA, where the typical reported total is $2,567.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$387,778in research payments, 2019–2025

Across 24 payments — averaging $16,157 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Deciphera Pharmaceuticals Inc.$258K
  • Merck$98K
  • AstraZeneca$31K

How this compares

$0 in reported general payments places this provider in the 10th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$23,062
Medicare patients
53
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prochlorperazine Maleate32$475
Dexamethasone33$192
LoperamideLoperamide Hcl15$120

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →